File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: High-grade lymphoma after azathioprine treatment for Vogt-Kaganayi-Harada syndrome

TitleHigh-grade lymphoma after azathioprine treatment for Vogt-Kaganayi-Harada syndrome
Authors
Hon, CHo, SLMa, ESKTrendellSmith, NJAu, WY
KeywordsAzathioprine
Lymphoma
Vogt-Kaganayi-Harada (VKH) syndrome
Issue Date2005
PublisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lal
Citation
Leukemia And Lymphoma, 2005, v. 46 n. 2, p. 289-292 How to Cite?
DOI: http://dx.doi.org/10.1080/10428190400015634
AbstractVogt-Kaganayi-Harada (VKH) syndrome is a rare autoimmune disease characterized by panuveitis, neuropathy and aseptic meningitis. Most patients require long-term treatment with steroids and immunosuppressants. Patients may develop concurrent autoimmune diseases, especially endocrinopathies. Secondary malignancies are rare associations. We report a Chinese man with VKH syndrome presenting with multiple cranial nerve palsy and bilateral pan-uveitis, who developed disseminated high-grade B cell lymphoma after 3-year treatment with azathioprine. This is the first report of systemic non-Hodgkin lymphoma in patients with VKH syndrome. The carcinogenic properties of azathioprine on an abnormally expanded but non-clonal lymphoid system may play a role in the pathogenesis. © 2005 Taylor & Francis Group Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/162784
ISSN
1042-8194
2023 Impact Factor: 2.2
2023 SCImago Journal Rankings: 0.790
ISI Accession Number ID
WOS:000225877800020
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorHon, Cen_US
dc.contributor.authorHo, SLen_US
dc.contributor.authorMa, ESKen_US
dc.contributor.authorTrendellSmith, NJen_US
dc.contributor.authorAu, WYen_US
dc.date.accessioned2012-09-05T05:23:29Z-
dc.date.available2012-09-05T05:23:29Z-
dc.date.issued2005en_US
dc.identifier.citationLeukemia And Lymphoma, 2005, v. 46 n. 2, p. 289-292en_US
dc.identifier.issn1042-8194en_US
dc.identifier.urihttp://hdl.handle.net/10722/162784-
dc.description.abstractVogt-Kaganayi-Harada (VKH) syndrome is a rare autoimmune disease characterized by panuveitis, neuropathy and aseptic meningitis. Most patients require long-term treatment with steroids and immunosuppressants. Patients may develop concurrent autoimmune diseases, especially endocrinopathies. Secondary malignancies are rare associations. We report a Chinese man with VKH syndrome presenting with multiple cranial nerve palsy and bilateral pan-uveitis, who developed disseminated high-grade B cell lymphoma after 3-year treatment with azathioprine. This is the first report of systemic non-Hodgkin lymphoma in patients with VKH syndrome. The carcinogenic properties of azathioprine on an abnormally expanded but non-clonal lymphoid system may play a role in the pathogenesis. © 2005 Taylor & Francis Group Ltd.en_US
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://informahealthcare.com/loi/lalen_US
dc.relation.ispartofLeukemia and Lymphomaen_US
dc.subjectAzathioprine-
dc.subjectLymphoma-
dc.subjectVogt-Kaganayi-Harada (VKH) syndrome-
dc.subject.meshAdulten_US
dc.subject.meshAzathioprine - Adverse Effectsen_US
dc.subject.meshCarcinogens - Adverse Effectsen_US
dc.subject.meshCranial Nerve Diseases - Diagnosis - Etiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunophenotypingen_US
dc.subject.meshLymph Nodes - Pathologyen_US
dc.subject.meshLymphoma, B-Cell - Chemically Induced - Etiologyen_US
dc.subject.meshLymphoma, Non-Hodgkin - Chemically Induced - Diagnosis - Etiologyen_US
dc.subject.meshMaleen_US
dc.subject.meshUveitis - Diagnosis - Etiologyen_US
dc.subject.meshUveomeningoencephalitic Syndrome - Complications - Drug Therapyen_US
dc.titleHigh-grade lymphoma after azathioprine treatment for Vogt-Kaganayi-Harada syndromeen_US
dc.typeArticleen_US
dc.identifier.emailHo, SL:slho@hku.hken_US
dc.identifier.authorityHo, SL=rp00240en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1080/10428190400015634en_US
dc.identifier.pmid15621816-
dc.identifier.scopuseid_2-s2.0-13244255333en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-13244255333&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume46en_US
dc.identifier.issue2en_US
dc.identifier.spage289en_US
dc.identifier.epage292en_US
dc.identifier.isiWOS:000225877800020-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridHon, C=7003617146en_US
dc.identifier.scopusauthoridHo, SL=25959633500en_US
dc.identifier.scopusauthoridMa, ESK=7202039934en_US
dc.identifier.scopusauthoridTrendellSmith, NJ=6602816986en_US
dc.identifier.scopusauthoridAu, WY=7202383089en_US
dc.identifier.citeulike26278-
dc.identifier.issnl1026-8022-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats